FDA Commissioner's stance on mifepristone availability
FDA Commissioner Martin Makary has stated he currently has no plans to restrict the availability of mifepristone, the first drug used in a two-drug medication abortion regimen, but may take action if data reveal dangers of the drug. Republican Sen. Josh Hawley criticized Makary's comments as disappointing.
Key Points
- Makary has no immediate plans to restrict mifepristone availability
- FDA may take action based on data indicating risks
- Increasing use of medication abortions in the U.S.
Pros
- Maintaining access to medication abortion for women
- Keeping a lookout for potential dangers through data analysis
Cons
- Potential risks associated with mifepristone
- Criticism from politicians and public figures